Paper Title
Anti-Cancer Agents & Intermediates Sector- Key Indicators for Due-Diligence & Funding

Abstract
The drug industry has a two-pronged approach on leaning on the research and development of innovative systems of diagnostics, pharmacology and drug discovery sciences on one side and the investment including the agencies for funding that need to be approached for advanced research on the other. The due-diligence or appraisal of the projects which seek funding for the manufacture and large scale production of the anti-cancer agents and intermediates needs a special approach even if an expert from the biosciences or molecular sciences is at the helm as the appraisal is not focused only on the crucial and more prominent aspects of the demand-supply gap, market analysis and financial viability in terms of return on investment but extrapolates to the legal guidelines, rules and regulations governing the manufacture of these drugs and the patentability of the drugs with exclusive marketing rights owing to the enhanced aspects of efficacy and efficiency portrayed and exhibited in the results of the pilot experimental studies. The paper is a proactive attempt at identifying the compulsory aspects of the due-diligence process, the viability of funding including the market assessment, risk benefit analysis andthe residual risk in the manufacture and large-scale production of the compounds, handling of the chemical compounds and requisition of expertise in the handling during the process. The paper adopts a case study of one of the laboratories that had approached for funding to the author, who was the analyst for the project proposed at a non-banking financial institution in the capacity of a technology-legal analyst. Keywords - Diagnostics, Pharmacology, Drug Discovery, Anti-Cancer Agents. Due-Diligence, Regulations, Market Analysis